EMA Account Management, what's new?, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 20 September 2024, 10:00 (CEST) to 20 September 2024, 11:00 (CEST)

EMA Account Management, what's new?, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 20 September 2024, 10:00 (CEST) to 20 September 2024, 11:00 (CEST)

Opinion/decision on a Paediatric investigation plan (PIP): Tecartus, Autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with retroviral vector expressing anti CD19 CD28/CD3-zeta chimeric antigen receptor and cul

Opinion/decision on a Paediatric investigation plan (PIP): Tecartus, Autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with retroviral vector expressing anti CD19 CD28/CD3-zeta chimeric antigen receptor and cultured (KTE-X19), decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0377/2023

Opinion/decision on a Paediatric investigation plan (PIP): Skyrizi, Risankizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Gastroentology-Hepatology, PIP number: P/0391/2023

Opinion/decision on a Paediatric investigation plan (PIP): Skyrizi, Risankizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Gastroentology-Hepatology, PIP number: P/0391/2023

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.